AlphAIAlphAI — Financial news for AI agents
SEC EDGARSEP 21 min read$QNRX

Carter Denise P. purchased $100K of QNRX

Carter Denise P. (Chief Operating Officer) purchased 20,490 shares of Quoin Pharmaceuticals, Ltd. (QNRX) at $4.88 on 2026-08-31.

Original reporting
SEC EDGAR · Carter Denise P.
Published Sep 2, 2026, 1:40 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 2, 2026, 1:54 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$QNRX
Bullish
medium confidence
Mentioned
$QNRX
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$QNRXBullishLow
01

Why it matters

The filing reveals a new $100K purchase by the COO, providing fresh insight into insider sentiment.

02

Market read

Insider buying could modestly influence QNRX stock price and signal confidence to investors.

03

What to watch

Potential upcoming clinical data could be the real driver.

Relevance 4/10Novelty 6/10Timing: post-market Aug 31

Background

SEC Form 4 filing discloses an insider transaction for Quoin Pharmaceuticals.

Company-level read

Ticker impact

$QNRXBullishMedium confidence
Context

COO Carter Denise P. purchased 20,490 shares of Quoin Pharmaceuticals at $4.88 per share, totaling $99,991.20.

Expected impact

modest upside potential

Evidence & confidence

The $100K buy is modest but signals insider belief; may lead to slight price lift.

Market effects

Sector

Biotech sector may view insider buying as a confidence signal.

Regional

US biotech market

Global

Limited to US markets

Counterpoint

What could challenge this read

Purchase size is small; may not indicate material change.

Key entities

  • company
    Quoin Pharmaceuticals, Ltd.

    Biotech company listed on NASDAQ under ticker QNRX.

  • person
    Carter Denise P.

    Chief Operating Officer of Quoin Pharmaceuticals.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

QNRX insider trading history →

Related articles

SEP 8
$QNRXMedAI 8/10

CORRECTION -- Quoin Pharmaceuticals Announces FDA Grants Rare Pediatric Disease Designation for QRX003 in Peeling Skin Syndrome

Quoin Pharmaceuticals (QNRX) announced FDA granted Rare Pediatric Disease Designation for QRX003, its treatment for Peeling Skin Syndrome. This is the second such designation for QRX003, following one for Netherton Syndrome. If approved, Quoin may receive a Priority Review Voucher. The company plans to initiate a Phase 2 study in 2H 2026, enrolling up to 12 patients. There are currently no approved treatments for Peeling Skin Syndrome.

globenewswire.com2 min
AUG 28
$AEMDHighAI 8/10

Biotech Gainers: QNRX Leads Gains As AEMD, DWTX And FRNM Report Key Developments

Aethlon Medical (AEMD) reported a 12% narrower Q1 loss and progress in its Hemopurifier study, with shares up 17.5%. Quoin Pharmaceuticals (QNRX) surged 34% pre-market on positive QRX003 data and a $50M financing. Dogwood Therapeutics (DWTX) gained 12% as its Halneuron trial advances. Freenome (FRNM) rose 7% after FDA Breakthrough Device Designation for its lung cancer test.

rttnews.com3 min
AUG 28
$QNRXHighAI 9/10

Quoin Pharma Reports Positive Interim Data From Ongoing Phase 2/3 Study Of QRX003

Quoin Pharmaceuticals (QNRX) reported positive interim results from its Phase 2/3 study of QRX003 for Netherton Syndrome. Four of six patients showed significant improvement. The company expects to complete recruitment by the end of 2026 and report topline data in Q2 2027. If approved, QRX003 could be the first FDA-approved treatment for the condition. QNRX shares rose 55% to $7.99 in pre-market trading.

rttnews.com2 min
AUG 14
$QNRXMed

Quoin Pharmaceuticals, Ltd. (QNRX): Results of Operations and Financial Condition

Quoin Pharmaceuticals, Ltd. (QNRX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Quoin Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2026 Financial Results – Receives FDA Conditional Approval of QYLEKI™ as the Proposed Brand Name for QRX003 for Netherton Syndrome – Reports Positive Clinical Update from Ongoing Pediatric Com

SEC EDGAR 8-K6 min